Pharmacokinetics of once daily intraperitoneal cefazolin in continuous ambulatory peritoneal dialysis patients

Journal of the American Society of Nephrology

Volumn 11, Issue 6, 2000, Pages 1117-1121

  Low, Chai Luan ^a   Gopalakrishna, Kamani ^a   Lye, Wai Choong ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CEFAZOLIN; VANCOMYCIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG URINE LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL;

EID: 0343674511     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/asn.v1161117     Document Type: Article

References (44)

1. Tranaeus A, Heimburger O, Lindholm B: Peritonitis in continuous ambulatory peritoneal dialysis (CAPD): Diagnostic findings, therapeutic outcome and complications. Perit Dial Int 9: 179-190, 1989
2. Rubin J, Rogers WA, Taylor HM, Everett ED, Prowant BF, Fruto LV, Nolph KD: Peritonitis during CAPD. Ann Intern Med 92: 7-13, 1980
3. Maiorca R, Cancarini GC, Brunori G, Camerini C, Manili L: Morbidity and mortality in CAPD and hemodialysis. Kidney Int 43[Suppl 40]: S4-S15, 1992
4. Port FK, Held PJ, Noplh KD, Turenne MN, Wolfe RA: Risk of peritonitis and technique failure by CAPD connection technique: A national study. Kidney Int 42: 967-974, 1992
5. Wu G: The university of Toronto collaborative dialysis group: A review of peritonitis episodes that cause interruption of CAPD. Perit Dial Bull 3: S11-S13, 1983
6. Read RR, Eberwein P, Dasgupta MK: Peritonitis in peritoneal dialysis: Bacterial colonization by biofilm spread along catheter surface. Kidney Int 35: 614-621, 1989
7. Verbrugh HA, Keane WF, Conroy WE: Bacterial growth and killing in chronic ambulatory peritoneal dialysis fluids. J Clin Microbiol 20: 199-203, 1984
8. Krothapali RK, Senekjian HO, Ayus JC: Efficacy of intravenous vancomycin in the treatment of Gram-positive peritonitis in long term peritoneal dialysis. Am J Med 15: 345-348, 1983
9. Keane WF, Everette ED, Fune RN: CAPD related peritonitis management and antibiotic therapy recommendations: Travenol peritonitis management advisory committee. Perit Dial Bull 7: 55-68, 1987
10. Bastani B, Freer K, Read D: Treatment of Gram-positive peritonitis with two intraperitoneal doses of vancomycin in CAPD patients. Nephron 45: 283-285, 1987
11. Hartford A, Sica D, Tartaglione T: Vancomycin pharmacokinetics in continuous ambulatory peritoneal dialysis (CAPD) patients with peritonitis. Kidney Int 25: 2574-2578, 1984
12. Wiley BM, Dreiswirth BN, Simor AE, William G, Scriver SR, Philips A: Detection of vancomycin resistance in Enterococcus species. J Clin Microbiol 30: 1621-1624, 1992
13. Noscomial enterococci resistant to vancomycin: United States 1989-1993. Morb Mortal Wkly Rep 42: 597-599, 1993
14. Lam S, Singer C, Tucci V, Morthland VH, Pfaller MA, Isenberg HD: The challenge of vancomycin-resistant enterococci: A clinical and epidemiological study. Am J Infect Control 23: 179-180, 1995
15. CDC: Staphylococcus aureus with reduced susceptibility to vancomycin: United States 1997. Morb Mortal Wkly Rep 46: 765-766, 1997
16. CDC: Reduced susceptibilty of Staphylococcus aureus to vancomycin: Japan 1996. MMWR 46: 624-626, 1997
17. Recommendations for preventing the spread of vancomycin resistance. Recommendations of Hospital Infection Control Practice Advisory Committee (HICPAC). Am J Infect Control 23: 87-94, 1995
18. Valentina S, Gary AN, Lance RP: The management and prevention of vancomycin resistant enterococci. Infect Med 13: 487-498, 1996
19. Keane WF, Alexander SR, Bailie GR, Boeschoten E, Gokal R, Golper TA: Peritoneal dialysis related peritonitis treatment recommendation: 1996 update. Perit Dial Int 16: 557-573, 1996
20. Quintiliani R, Charles H, Nightingale CH: Cefazolin. Ann Intern Med 89: 650-656, 1978
21. Sabath LD, Wilcox C, Carol G, Finland M: In vitro activity of cefazolin against recent clinical bacterial isolates. J Infect Dis 128[Suppl]: S320-S326, 1973
22. Craig WA, Welling PG, Jackson TC, Kunin CM: Pharmacology of cefazolin and other cephalosporins in patients with renal insufficiency. J Infect Dis 128[Suppl]: S347-S355, 1973
23. William M, Kirby M, Claude R: Pharmacology of cefazolin compared with four other cephalosporins. J Infect Dis 128[Suppl]: S341-S346, 1973
24. Nishida M, Matsubara T, Murakawa T, Mine Y: In vitro and in vivo evaluation of cefazolin, a new cephalosporin C derivative. Antimicrob Agents Chemother 69: 236-243, 1971
25. Neal D, Bailie GR: Clearance from dialysate and equilibration of intraperitoneal vancomycin in continuous ambulatory peritoneal dialysis. Clin Pharmacokinet 18: 485-490, 1990
26. Gopalakrishna K, Low CL, Tan HHV, Chui WK: HPLC determination of cefazolin in plasma, urine and dialysate. J Pharm Pharmacol 50[Suppl]: 118, 1998
27. Nahata MC, Ahalt PA: Stability of cefazolin sodium in peritoneal dialysis solutions. Am J Hosp Pharmacol 48: 291-292, 1991
28. Low CL, Ballie GR, Evans A, Eisele G, Venezia RA: Pharmacokinetics of once daily IP gentamicin in CAPD patients. Perit Dial Int 16: 379-384, 1995
29. Lameire N, Belpaire F: Pharmacokinetics of antibiotics against Gram-negative infections in CAPD patients. Perit Dial Int 13[Suppl]: S371-S376, 1993
30. De Paepe M, Lameire N, Belpaire F, Bogaert M: Peritoneal pharmacokinetics of gentamicin in man. Clin Nephrol 19: 107-109, 1983
31. Bastani B, Spijker DA, Westevelt FB: Peritoneal absorption of vancomycin during and after resolution of peritonitis in continuous ambulatory peritoneal dialysis (CAPD) patients. Perit Dial Int 8: 135-136, 1988
32. Imada A, Itagaki N, Hasegawa H, Horiuchi A: Comparative study of the pharmacokinetics of various beta-lactam after intravenous and intraperitoneal administration in patients undergoing continuous ambulatory peritoneal dialysis. Drugs 35: 82-87, 1988
33. Madhavan T, Yaremchuk K, Kevin N, Fisher E, Cox F, Burch K: Effects of renal failure and dialysis on cefazolin pharmacokinetics. Antimicrob Agents Chemother 8: 63-66, 1975
34. Czerwinski AW, Pederson JA, Barry JP: Cefazolin plasma concentration and urinary excretion in patients with renal impairment. J Clin Pharmacol 14: 560-566, 1974
35. Leroy A, Marc-andre C, Jean-Paul F, Humbert G: Pharmacokinetics of cefazolin a new cephalosporin antibiotic in normal and uremic patients. Curr Ther Res 16: 878-889, 1974
36. Vincent TA: Pharmacokinetic of cephalosporin in patients with normal and reduced renal function. J Infect Dis 135[Suppl]: S88-S97, 1978
37. Welling PG, Craig WA, Amidon GL, Kunin CM: Pharmacokinetics of cefazolin in normal and uremic subjects. Clin Pharmacol Ther 15: 344-353, 1973
38. Bunke CM, Aronoff GR, Brier ME, Sloan R, Luft FC: Cefazolin and cephalexin kinetics in CAPD. Clin Pharmacol Ther 33: 66-71, 1983
39. Golper T: Intermittent versus continuous antibiotics for PD-related peritonitis. Perit Dial Int 17: 11-12, 1997
40. Vas S, Bargman J, Oreopoulos DG: Treatment of PD patients of peritonitis caused by Gram-positive organisms with single daily dose of antibiotics. Perit Dial Int 17: 91-94, 1997
41. Lai MN, Kao MT, Chen CC, Cheung SY, Chung WK: Intraperitoneal once daily dose of cefazolin and gentamicin for treating CAPD peritonitis. Pent Dial Int 17: 87-89, 1997
42. Bunke M, Brier ME, Golper TA: Culture-negative CAPD peritonitis: The network 9 study. Perit Dial Int 10: 174-178, 1994
43. Fogel MA, Nussbaum PB, Feintzeig ID, Hunt WA, Gavin JP, Kim RC: Cefazolin in chronic hemodialysis patients: A safe, effective alternative to vancomycin. Am J Kidney Dis 32: 401-409, 1998
44. Marx MA, Frye RF, Matzke GR, Golper TA: Cefazolin as empiric therapy in hemodialysis-related infections: Efficacy and blood concentrations. Am J Kidney Dis 32: 410-414, 1998